« Return to News | Technology Solutions

ClearTrial Launches Study Forecasting Service

Tuesday, March 16, 2010 06:30 AM

ClearTrial, a provider of clinical trial software, recently launched its Study Costing and Optimization Service (SCOS), a product that combines ClearTrial’s existing trial management software with the consultation services of the company’s clinical services staff. ClearTrial said the new offering will give smaller biopharma companies more control over clinical trial costs, resources and timelines.

As part of the SCOS, ClearTrials provides a clinical services manager who works with a client’s internal clinical team to generate detailed cost, resource and timeline reports for multiple study scenarios. These scenarios enable the client to analyze different possible cost- and time-cutting measures.

"Many smaller biopharma companies lack the visibility to accurately forecast clinical trials, leading to them not understanding how much clinical trials should really cost, as well as dealing with unforeseen shifts in trial timelines," said Andrew Grygiel, vice president of marketing and product management, in a statement. “We conducted an extensive pilot program of the ClearTrial Study Costing and Optimization Service, and, in every case, were able to identify dramatic reductions in study costs and timelines, while ensuring that the studies were still achievable."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.